The AREL1 (Apoptosis-Resistant E3 Ubiquitin-Protein Ligase 1) antibody is a research tool designed to detect AREL1. a protein implicated in cellular stress responses and apoptosis regulation. AREL1. also known as RNF216L, belongs to the RBR (RING-between-RING) family of E3 ubiquitin ligases, characterized by their role in ubiquitination—a post-translational modification critical for protein degradation, signaling, and homeostasis. Structurally, AREL1 contains a conserved RING domain essential for its enzymatic activity, enabling substrate recognition and ubiquitin transfer.
Biologically, AREL1 is linked to endoplasmic reticulum (ER)-associated degradation (ERAD) and the unfolded protein response (UPR), processes that mitigate ER stress by tagging misfolded proteins for proteasomal clearance. Dysregulation of AREL1 has been associated with neurodegenerative diseases, cancer, and immune disorders, where impaired protein homeostasis contributes to pathogenesis. For instance, AREL1 overexpression in certain cancers may promote cell survival by suppressing pro-apoptotic signals, highlighting its therapeutic relevance.
The AREL1 antibody is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study protein expression, localization, and interactions. It aids in exploring AREL1's role in disease mechanisms, drug response, and as a potential biomarker. Researchers prioritize validating antibody specificity using knockout controls to ensure accurate detection. Overall, AREL1 antibodies are pivotal in unraveling the protein's functional dynamics and its implications in health and disease.